Elkord, Eyad

Immune checkpoint inhibitors: recent progress and potential biomarkers

Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,035

Immune evasion in cancer: mechanistic basis and therapeutic strategies

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,625

Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression

Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 292

Neuropilin 1: function and therapeutic potential in cancer

Chaudhary, B., Khaled, Y. S., Ammori, B. J., & Elkord, E. (2014) · Cancer Immunology, Immunotherapy

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 233

Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells

Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018) · Expert Opinion on Therapeutic Targets

Cancer Immunotherapy and BiomarkersCytokine Signaling Pathways and Interactions

Cited by 159

Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP

Elkord, E., Abd Al Samid, M., & Chaudhary, B. (2015) · Oncotarget

T-cell and B-cell ImmunologyPsoriasis: Treatment and Pathogenesis

Cited by 94